|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Syndax Pharmaceuticals Inc.
| | | Phone: | (646) 690-7620 | Fax: | (212) 867-5902 | Year Established: | 2005 | Ticker: | SNDX | Exchange: | NASDAQ | Main Contact: | Briggs W. Morrison, M.D., CEO | | Other Contacts: | Richard P. Shea, CFO Peter Ordentlich, Ph.D., CSO & Founder Michael L. Meyers, M.D., Ph.D., CMO Michael A. Metzger, President & COO
| | Company Description | Syndaxis is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody. | |
|
|
|
|
|